Letters to the Editor
You have free access to this content
Letter: sorafenib in portal hypertension
Article first published online: 16 OCT 2012
DOI: 10.1111/apt.12067
© 2012 Blackwell Publishing Ltd
Additional Information
How to Cite
Procopet, B., Bureau, C. and Peron, J. M. (2012), Letter: sorafenib in portal hypertension. Alimentary Pharmacology & Therapeutics, 36: 994. doi: 10.1111/apt.12067
Publication History
- Issue published online: 16 OCT 2012
- Article first published online: 16 OCT 2012
- Manuscript Accepted: 12 SEP 2012
- Manuscript Received: 11 SEP 2012
References
- 1, , , , , . The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma–a pilot study. Aliment Pharmacol Ther 2012; 35: 83–91.
- 2, , , , , . Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009; 49: 1245–56.

1365-2036/asset/olbannerleft.gif?v=1&s=45db8c78d1d41c404034f2eaf7587620d5727843)
1365-2036/asset/olbannerright.gif?v=1&s=45518840b7e2e59fcc9d74113b13f4474a604878)
